And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is, so far, rather modest. We plan to tidy up around the castle, catch up on our reading, and promenade with the official mascots. We also expect to hold another listening party, where the rotation will likely include this, this, this, this, this and this. And what about you? Some distraction from the world at large may be in order and there is nothing like a romp through an apple orchard or pumpkin patch to lift the spirits. If the weather does not cooperate, though, you could always binge-watch something on the telly or cook up an exotic meal. Or perhaps make time to see someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
Heidi Overton, President Trump’s nominee to lead the U.S. Food and Drug Administration, was grilled by senators on hot button topics like China, vaccines, and abortion access in her hearing before the committee that will decide whether to send her nomination for a vote of the full Senate, but revealed very little of her own feelings on top issues facing the agency, STAT writes. Instead, she referred repeatedly to existing agency guidance and approvals for products like childhood vaccines and the abortion drug mifepristone — without saying whether she would endorse updating those guidances or altering approvals to satisfy the desires of Trump or health secretary Robert F. Kennedy Jr.
Novo Nordisk agreed to pay up to $1.3 billion to license and develop Nanexa’s drug delivery technology in a deal that could cut the frequency that patients need to inject its obesity and diabetes drugs, The Wall Street Journal writes. The deal covers Nanexa’s PharmaShell technology, which is designed to enable controlled and sustained release of active pharmaceutical ingredients through an ultra-thin coating applied to individual drug particles. Under the exclusive deal, Novo licensed Nanexa’s technology in up to five development programs covering different drug administration frequencies, with the companies targeting monthly and quarterly administration.
